All issues
Volume 139 (2012)
- Issue 6 Pages 236-
- Issue 5 Pages 193-
- Issue 4 Pages 142-
- Issue 3 Pages 93-
- Issue 2 Pages 52-
- Issue 1 Pages 6-
Volume 139, Issue 4
Displaying 1-8 of 8 articles from this issue
- |<
- <
- 1
- >
- >|
Reviews: Environmental Insults That Precipitate Psychiatric Disorders on Multiple Life Stages and the Implications for Pharmaceutical Development
-
Taku Yamaguchi, Hiroko Togashi, Machiko Matsumoto, Takeshi Izumi, Mits ...2012 Volume 139 Issue 4 Pages 142-146
Published: 2012
Released on J-STAGE: April 10, 2012
JOURNAL OPEN ACCESS -
Taku Nagai, Jaesk Yun, Daisuke Ibi, Hiroyuki Koike, Yoko Hibi, Kiyofum ...2012 Volume 139 Issue 4 Pages 147-151
Published: 2012
Released on J-STAGE: April 10, 2012
JOURNAL OPEN ACCESS -
Kohei Tanaka, Tomoyuki Furuyashiki2012 Volume 139 Issue 4 Pages 152-156
Published: 2012
Released on J-STAGE: April 10, 2012
JOURNAL OPEN ACCESS -
Ming Teng Koh2012 Volume 139 Issue 4 Pages 157-159
Published: 2012
Released on J-STAGE: April 10, 2012
JOURNAL OPEN ACCESSAmnestic mild cognitive impairment (aMCI) is associated with increased activation in the CA3-dentate region of hippocampus. Excess CA3 activity also occurs in aged rats with memory impairment. Therapies to counter such excess activity might include antiepileptics or agonists for GABAA α5 receptors, which regulate tonic inhibition. Use of GABAA α5 agonists may seem unexpected because GABAA α5 inverse agonists were developed as cognitive enhancers. We found that inverse agonists, while yielding benefit in normal young adult rats, are not effective in treating memory loss in aged rats. Instead, aged rats showed improved memory after treatment with selective GABAA α5 agonists and with certain antiepileptics. These benefits of treatment are consistent with the concept that excess activity in the CA3 of the hippocampus is a dysfunctional condition contributing to age-associated memory impairment. Because excess hippocampal activation is also observed in aMCI, our findings support the use of antiepileptic or GABAA α5 agonist therapy in aMCI. Such therapy, in addition to memory improvement, may also have disease modifying potential because hippocampal overactivity in aging/MCI predicts further cognitive decline and conversion to Alzheimer’s disease.View full abstractDownload PDF (306K)
Review
-
Yasushi Kuraishi2012 Volume 139 Issue 4 Pages 160-164
Published: 2012
Released on J-STAGE: April 10, 2012
JOURNAL OPEN ACCESS -
Eiichi Hinoi, Yukio Yoneda2012 Volume 139 Issue 4 Pages 165-169
Published: 2012
Released on J-STAGE: April 10, 2012
JOURNAL OPEN ACCESS
Review: Pre- and Post-Approval Drug Development
-
Toshihiro Sakakibara2012 Volume 139 Issue 4 Pages 170-173
Published: 2012
Released on J-STAGE: April 10, 2012
JOURNAL OPEN ACCESS
Review on New Drug
-
Tsuyoshi Ohmura, Naoyuki Hayashi, Jeffrey Encinas2012 Volume 139 Issue 4 Pages 174-183
Published: 2012
Released on J-STAGE: April 10, 2012
JOURNAL OPEN ACCESS
- |<
- <
- 1
- >
- >|